| Prostate Adenocarcinoma altered in cohorts of …ALTERED_INderived144 of 144show fewer |
|---|
| ← altered in cohorts of | CCAR2 298 / 500 cases (60 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BIN3 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C8orf58 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XPO7 297 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEBP4 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP3CC 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RHOBTB2 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SORBS3 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10C 296 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DMTN 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOK2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EGR3 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM160B2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HR 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDLIM2 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR3D 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | REEP4 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10A 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10D 295 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHMP7 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF17 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LGI3 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LOXL2 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NKX3-1 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPM2 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUDT18 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHYHIP 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | R3HCC1 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SFTPC 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC25A37 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A14 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10B 294 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM28 293 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENTPD4 293 / 500 cases (59 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NKX2-6 292 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM7 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMDEC1 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STC1 291 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GFRA2 290 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LZTS1 289 / 500 cases (58 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP6V1B2 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDCA2 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC18A1 286 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS10 284 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPL 284 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSGALNACT1 283 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOCK5 283 / 500 cases (57 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPYSL2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EBF2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCTD9 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEFL 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEFM 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PNMA2 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPP2R2A 282 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADRA1A 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIP3L 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNRH1 281 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D4A 279 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM35 278 / 500 cases (56 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNA2 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSD3 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTK2B 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STMN4 277 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPHX2 276 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAT2 275 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC25 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESCO2 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAT1 273 / 500 cases (55 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAH1 272 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCM1 272 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLU 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGL1 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBK 271 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTUS1 270 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCARA3 270 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCARA5 269 / 500 cases (54 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUGGC 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDGFRL 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A2 267 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELP3 265 / 500 cases (53 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTMR7 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PNOC 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SGCZ 262 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSR1 261 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TUSC3 261 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNOT7 260 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF395 260 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DLC1 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS37A 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZDHHC2 259 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C8orf48 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EXTL3 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO16 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FZD3 258 / 500 cases (52 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF20 257 / 500 cases (51 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LONRF1 257 / 500 cases (51 %) · ssm · TCGA-PRAD | — | — | Prostate Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IDH1 29 / 99 cases (29 %) · ssm · prad_idhmut_msk_2025 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 551 / 2,069 cases (27 %) · ssm · prad_msk_stopsack_2021 · largest of 17 cohorts | — | — | Prostate Adenocarcinoma | 17 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FRG1BP 97 / 499 cases (19 %) · ssm · prad_tcga | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TTN 151 / 1,013 cases (15 %) · ssm · prad_p1000 · largest of 8 cohorts | — | — | Prostate Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AR 61 / 444 cases (14 %) · ssm · prad_su2c_2019 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FOXA1 273 / 2,069 cases (13 %) · ssm · prad_msk_stopsack_2021 · largest of 10 cohorts | — | — | Prostate Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPOP 260 / 2,069 cases (13 %) · ssm · prad_msk_stopsack_2021 · largest of 12 cohorts | — | — | Prostate Adenocarcinoma | 12 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 113 / 1,013 cases (11 %) · ssm · prad_p1000 · largest of 7 cohorts | — | — | Prostate Adenocarcinoma | 7 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BRCA2 37 / 444 cases (8.3 %) · ssm · prad_su2c_2019 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AHNAK2 35 / 444 cases (7.9 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PTEN 155 / 2,069 cases (7.5 %) · ssm · prad_msk_stopsack_2021 · largest of 6 cohorts | — | — | Prostate Adenocarcinoma | 6 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SYNE1 73 / 1,013 cases (7.2 %) · ssm · prad_p1000 · largest of 4 cohorts | — | — | Prostate Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | USH2A 31 / 444 cases (7.0 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2C 140 / 2,069 cases (6.8 %) · ssm · prad_msk_stopsack_2021 · largest of 10 cohorts | — | — | Prostate Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| ← altered in cohorts of | APC 138 / 2,069 cases (6.7 %) · ssm · prad_msk_stopsack_2021 · largest of 6 cohorts | — | — | Prostate Adenocarcinoma | 6 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC17 33 / 499 cases (6.6 %) · ssm · prad_tcga · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CACNA1E 29 / 444 cases (6.5 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2D 133 / 2,069 cases (6.4 %) · ssm · prad_msk_stopsack_2021 · largest of 9 cohorts | — | — | Prostate Adenocarcinoma | 9 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PLEC 28 / 444 cases (6.3 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR1 28 / 444 cases (6.3 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATM 27 / 444 cases (6.1 %) · ssm · prad_su2c_2019 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DCHS2 27 / 444 cases (6.1 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT3 27 / 444 cases (6.1 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD3 61 / 1,013 cases (6.0 %) · ssm · prad_p1000 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC4 26 / 444 cases (5.9 %) · ssm · prad_su2c_2019 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR3 26 / 444 cases (5.9 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX3 110 / 1,924 cases (5.7 %) · ssm · prad_msk_stopsack_2021 · largest of 3 cohorts | — | — | Prostate Adenocarcinoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CDK12 118 / 2,069 cases (5.7 %) · ssm · prad_msk_stopsack_2021 · largest of 5 cohorts | — | — | Prostate Adenocarcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PIK3CA 24 / 424 cases (5.7 %) · ssm · prad_mcspc_mskcc_2020 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ABCA13 25 / 444 cases (5.6 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MACF1 25 / 444 cases (5.6 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR2 25 / 444 cases (5.6 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HMCN1 55 / 1,013 cases (5.4 %) · ssm · prad_p1000 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CTNNB1 23 / 424 cases (5.4 %) · ssm · prad_mcspc_mskcc_2020 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NBPF1 27 / 499 cases (5.4 %) · ssm · prad_tcga | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANK2 24 / 444 cases (5.4 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT4 24 / 444 cases (5.4 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TENM3 24 / 444 cases (5.4 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 54 / 1,013 cases (5.3 %) · ssm · prad_p1000 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OBSCN 53 / 1,013 cases (5.2 %) · ssm · prad_p1000 · largest of 2 cohorts | — | — | Prostate Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPTA1 26 / 499 cases (5.2 %) · ssm · prad_tcga | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD1 23 / 444 cases (5.2 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DST 23 / 444 cases (5.2 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP2 23 / 444 cases (5.2 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PKHD1 23 / 444 cases (5.2 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX4 23 / 444 cases (5.2 %) · ssm · prad_su2c_2019 | — | — | Prostate Adenocarcinoma | 1 | Observed | cbioportal | graph → |